

## Compensation Results by NIOSH-IREP Cancer Model

Based on Claims with DR Approved and Submitted to DOL through December 17, 2019 (44,366 Claims)

Claims with a Single Primary Cancer							
Rank by Compensation Rate	NIOSH-IREP Cancer Model (ICD-9 Code)	Compensated (PC ≥ 50%)		Not Compensated (PC < 50%)		Total Claims	
		N	%	N	%	N	%
1	Lung (162)	3460	62.5	2079	37.5	5539	18.4
2	Non-melanoma skin-Basal Cell (173)	1351	52.0	1247	48.0	2598	8.6
3	Chronic Myeloid Leukemia (205.1)	61	50.4	60	49.6	121	0.4
4	Acute Lymphocytic Leukemia (204.0)	45	43.3	59	56.7	104	0.3
5	Lymphoma & multiple myeloma (200-203)	856	37.9	1404	62.1	2260	7.5
6	Liver (155.0)	102	37.4	171	62.6	273	0.9
7	Acute Myeloid Leukemia (205.0)	81	33.2	163	66.8	244	0.8
8	Malignant melanoma (172)	308	32.9	628	67.1	936	3.1
9	Chronic Lymphocytic Leukemia (204.1)	102	31.8	219	68.2	321	1.1
10	Leukemia, excl. CLL (204-208,excl. 204.1)	48	30.2	111	69.8	159	0.5
11	Other respiratory (160,161,163-165)	231	29.7	548	70.3	779	2.6
12	Oral Cavity and Pharynx (140-149)	114	19.4	473	80.6	587	2.0
13	Bone (170)	48	16.2	248	83.8	296	1.0
14	Thyroid (193)	67	14.4	398	85.6	465	1.5
15	Gallbladder (155.1,156)	20	13.5	128	86.5	148	0.5
16	Stomach (151)	64	9.6	606	90.4	670	2.2
17	Colon (153)	114	7.5	1397	92.5	1511	5.0
18	Eye (190)	5	7.5	62	92.5	67	0.2
19	Bladder (188)	51	6.3	756	93.7	807	2.7
20	Urinary organs, excluding bladder (189)	51	6.3	760	93.7	811	2.7
21	Other and ill-defined sites (195)	5	5.7	83	94.3	88	0.3
22	All Male Genitalia (185-187)	212	3.7	5590	96.3	5802	19.3
23	Other endocrine glands (194)	1	2.9	33	97.1	34	0.1
24	Connective tissue (171)	6	2.9	203	97.1	209	0.7
25	Esophagus (150)	5	2.5	195	97.5	200	0.7
26	All digestive (150-159)	4	2.5	158	97.5	162	0.5
27	Non-melanoma skin-Squamous Cell (173)	17	1.7	989	98.3	1006	3.3
28	Breast (174-175)	19	1.4	1357	98.6	1376	4.6
29	Rectum (154)	8	1.2	642	98.8	650	2.2
30	Pancreas (157)	9	1.2	756	98.8	765	2.5
31	Ovary (183)	1	0.6	165	99.4	166	0.6
32	Nervous system (191-192)	3	0.6	531	99.4	534	1.8
33	Female Genitalia, excl. ovary(179-182,184)	0	0.0	372	100.0	372	1.2
<b>Subtotal for Claims with a Single Primary Cancer</b>		<b>7469</b>	<b>24.8</b>	<b>22591</b>	<b>75.2</b>	<b>30060</b>	<b>67.8</b>
<b>Subtotal for Claims with 2 Primary Cancers</b>		<b>2048</b>	<b>27.8</b>	<b>5326</b>	<b>72.2</b>	<b>7374</b>	<b>16.6</b>
<b>Subtotal for Claims with 3 Primary Cancers</b>		<b>992</b>	<b>36.5</b>	<b>1723</b>	<b>63.5</b>	<b>2715</b>	<b>6.1</b>
<b>Subtotal for Claims with 4 Primary Cancers</b>		<b>1630</b>	<b>38.7</b>	<b>2587</b>	<b>61.3</b>	<b>4217</b>	<b>9.5</b>
<b>Subtotal for Claims with Multiple Primary Cancers</b>		<b>4670</b>	<b>32.6</b>	<b>9636</b>	<b>67.4</b>	<b>14306</b>	<b>32.2</b>
<b>GRAND TOTAL (ALL CLAIMS)</b>		<b>12139</b>	<b>27.4</b>	<b>32227</b>	<b>72.6</b>	<b>44366</b>	<b>100.0</b>

The data presented on this page: may not be predictive of future results; reflect claims that were evaluated using a single primary cancer (unless otherwise noted); and, are in some cases based on a small number of cases.

The data present on this page are indicative of compensation rates for claims that have gone through dose reconstruction and do not include claims that have been awarded compensation through the Special Exposure Cohort (SEC) process. Thus, overall compensation rates for the 22 cancers that are included in the SEC may be higher.

